Metformin use and gynecological cancers: a novel treatment option emerging from drug repositioning

A Gadducci, N Biglia, R Tana, S Cosio… - Critical reviews in oncology …, 2016 - Elsevier
Metformin exerts antitumor effects mainly through AMP-activated protein kinase [AMPK]
activation and phosphatidylinositol 3-kinase [PI3K]-Akt-mammalian target of rapamycin …
被引用次数：109 相关文章

Metformin use and gynecological cancers: A novel treatment option emerging from drug repositioning.

A Gadducci, N Biglia, R Tana, S Cosio… - Critical Reviews in …, 2016 - europepmc.org
Metformin exerts antitumor effects mainly through AMP-activated protein kinase [AMPK]
activation and phosphatidylinositol 3-kinase [PI3K]-Akt-mammalian target of rapamycin …
[PDF] publicationslist.org

[PDF][PDF] Metformin use and gynecological cancers: A novel treatment option emerging from drug repositioning

A Gadducci, N Biglia, R Tana, S Cosio… - Critical Reviews in …, 2016 - publicationslist.org
abstract Metformin exerts antitumor effects mainly through AMP-activated protein kinase
[AMPK] activation and phosphatidylinositol 3-kinase [PI3K]-Akt-mammalian target of …

[引用][C] Metformin use and gynecological cancers: A novel treatment option emerging from drug repositioning

A Gadducci, N Biglia, R Tana, S Cosio… - Critical Reviews in …, 2016 - cir.nii.ac.jp
Metformin use and gynecological cancers: A novel treatment option emerging from drug
repositioning | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …

Metformin use and gynecological cancers: A novel treatment option emerging from drug repositioning

A Gadducci, N Biglia, R Tana, S Cosio… - CRITICAL REVIEWS IN …, 2016 - iris.unito.it
Metformin exerts antitumor effects mainly through AMP-activated protein kinase [AMPK]
activation and phosphatidylinositol 3-kinase [PI3K]-Akt-mammalian target of rapamycin …

Metformin use and gynecological cancers: A novel treatment option emerging from drug repositioning

A Gadducci, N Biglia, R Tana… - Critical reviews in …, 2016 - pubmed.ncbi.nlm.nih.gov
Metformin exerts antitumor effects mainly through AMP-activated protein kinase [AMPK]
activation and phosphatidylinositol 3-kinase [PI3K]-Akt-mammalian target of rapamycin …

Metformin use and gynecological cancers: A novel treatment option emerging from drug repositioning

A Gadducci, N Biglia, R Tana, S Cosio… - Critical Reviews in …, 2016 - infona.pl
Metformin exerts antitumor effects mainly through AMP-activated protein kinase [AMPK]
activation and phosphatidylinositol 3-kinase [PI3K]-Akt-mammalian target of rapamycin …

Metformin use and gynecological cancers: A novel treatment option emerging from drug repositioning.

A Gadducci, N Biglia, R Tana, S Cosio… - CRITICAL REVIEWS IN …, 2016 - arpi.unipi.it
Metformin exerts antitumor effects mainly through AMP-activated protein kinase [AMPK]
activation and phosphatidylinositol 3-kinase [PI3K]-Akt-mammalian target of rapamycin …